TW200730172A - Cyclohexane derivatives - Google Patents

Cyclohexane derivatives

Info

Publication number
TW200730172A
TW200730172A TW095144075A TW95144075A TW200730172A TW 200730172 A TW200730172 A TW 200730172A TW 095144075 A TW095144075 A TW 095144075A TW 95144075 A TW95144075 A TW 95144075A TW 200730172 A TW200730172 A TW 200730172A
Authority
TW
Taiwan
Prior art keywords
group
optionally substituted
cr3r4
containing aromatic
independently represents
Prior art date
Application number
TW095144075A
Other languages
Chinese (zh)
Inventor
Moriyasu Masui
Hidenori Mikamiyama
Naoki Tsuno
Akira Matsumura
Hiroyuki Kai
Kousuke Anan
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of TW200730172A publication Critical patent/TW200730172A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention provides a cyclohexane derivative of the following formula (I), (wherein, A1 represents an optionally substituted N-containing aromatic monocyclo group or an optionally substituted N-containing aromatic condensed cyclo group, said N-containing aromatic monocyclo group or N-containing aromatic condensed cyclo group satisfys at least one of following condition: (i) having at least one of a group selected from an optionally protected hydroxy group, an optionally protected amino group and an optionally substituted aminoxy group, or (ii) containing -NH- in the cycle, A2 represents an optionally substituted aromatic cyclohydrocarbon group etc., each of the R1, R2a, R2b and R2c independently represents a hydrogen atom or a hydroxy group etc., m represents 0 or 1, X independently represents an optionally substituted lower alkenylene group, -CO(CR3R4)n-, -CONR5(CR3R4)n-, -NR5CO(CR3R4)n-, -A3-(CR3R4)n- etc., R3 and R4 independently represents a hydrogen atom or a lower alkyl group, each of n, r and s independently represents an integer of 0~4, qrepresents an integer of 0~4, A3 represents a phenylene group, a pyridinylene group etc., Y represents a single bond, a lower alkylene group, -O-, -S- or -NR15- etc., each of the R3~R16independently represents a hydrogen atom or an optionally substituted lower alkyl group), or the pharmaceutically acceptable salt or solvate thereof, which can specifically bind with the receptors of NR1/NR2B and can be used as analgesic.
TW095144075A 2005-11-30 2006-11-29 Cyclohexane derivatives TW200730172A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005345252 2005-11-30

Publications (1)

Publication Number Publication Date
TW200730172A true TW200730172A (en) 2007-08-16

Family

ID=38092172

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095144075A TW200730172A (en) 2005-11-30 2006-11-29 Cyclohexane derivatives

Country Status (3)

Country Link
JP (1) JPWO2007063839A1 (en)
TW (1) TW200730172A (en)
WO (1) WO2007063839A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
EP2345328A4 (en) * 2008-09-19 2014-06-25 Sumitomo Chemical Co Composition for agricultural use
WO2013156614A1 (en) 2012-04-20 2013-10-24 Ucb Pharma S.A. Methods for treating parkinson's disease
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN107205970A (en) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 Immunomodulator
CA2973873A1 (en) * 2015-01-20 2016-07-28 Merial, Inc. Anthelmintic compounds, compositions and method of using thereof
CN110357813A (en) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69730980T2 (en) * 1996-07-31 2006-02-23 Nikken Chemicals Co., Ltd. 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ON DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEY
US6291499B1 (en) * 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
ATE301642T1 (en) * 2000-06-06 2005-08-15 Warner Lambert Co BICYCLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTAGONISTS
WO2002024613A2 (en) * 2000-09-21 2002-03-28 Pfizer Products, Inc. Resorcinol derivatives
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
MXPA02002749A (en) * 2001-03-27 2002-10-28 Warner Lambert Co Cyclohexylamine derivatives as subtype selective n-methyl-d-aspartate antagonists.
WO2003045920A1 (en) * 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
MXPA05005425A (en) * 2002-11-22 2005-11-23 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocycles.
MXPA05006487A (en) * 2002-12-17 2005-08-26 Pfizer 2-pyridyl and 2-pyrimidyl cycloalkylene amide compounds as nr2b receptor antagonists.
DE602004004278T2 (en) * 2003-08-15 2007-10-31 Merck & Co, Inc. 4-CYCLOALKYLAMINOPYRAZOLOPYRIMIDINE AS NMDA / NR2B ANTAGONISTS
CA2555970A1 (en) * 2004-02-11 2005-09-01 Pfizer Inc. Therapeutic amide derivatives

Also Published As

Publication number Publication date
JPWO2007063839A1 (en) 2009-05-07
WO2007063839A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
TW200730172A (en) Cyclohexane derivatives
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
EP2520567A3 (en) Nitrogen-containing heterocycle derivatives substituted with cyclic group
MX2010008745A (en) Fibrosis inhibitor.
TW200716576A (en) Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TW200600508A (en) Cyclic amide derivative, and its production and use
MY144588A (en) Novel coumarin derivative having antitumor activity
WO2009005152A1 (en) Novel lipid-tripeptide based hydrogel-forming agent and hydrogel
PT2280706E (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
TW200642683A (en) Heterocyclic compound
SG155180A1 (en) Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
MY146042A (en) Water-soluble benzoazepine compound and its pharmaceutical composition
TW200720252A (en) Cyclic amine derivative having substituted alkyl group
GB2442148A (en) FK 228 derivates as HDAC inhibitors
WO2004000808A3 (en) N-substituted piperidine derivatives as serotonin receptor agents
EP1921077A4 (en) Agent for treating and/or preventing sleep disorder
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
RS52881B (en) Benzamide compunds useful as histone deacetylase inhibitors
WO2008099874A1 (en) Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination
WO2007056091A3 (en) 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof
MX2009008756A (en) Macrocyclic compound.
WO2007121389A3 (en) 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors
WO2008149834A1 (en) Pyrimidodiazepinone derivative
MX2009004314A (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof.